Last reviewed · How we verify
ATHENA CAR-T
CAR-T cell therapy targeting CD19
CAR-T cell therapy targeting CD19 Used for Relapsed or refractory B-cell acute lymphoblastic leukemia, Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | ATHENA CAR-T |
|---|---|
| Also known as | ET-901 |
| Sponsor | EdiGene Inc. |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
A type of immunotherapy that uses genetically modified T cells to recognize and attack cancer cells expressing CD19.
Approved indications
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (PHASE1, PHASE2)
- TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATHENA CAR-T CI brief — competitive landscape report
- ATHENA CAR-T updates RSS · CI watch RSS
- EdiGene Inc. portfolio CI